DNX Biopharmaceuticals Announces Collaboration With Lung Cancer Initiative at Johnson & Johnson
San Diego, California--(Newsfile Corp. - February 18, 2020) - DNX Biopharmaceuticals, a biopharmaceutical company developing long-acting therapeutic proteins for the treatment of patients with life-long diseases and a resident of Johnson & Johnson Innovation - JLABS, Shanghai, announced today that it has entered into a strategic collaboration with the Lung Cancer Initiative at Johnson & Johnson*. Under terms of the agreement, the Lung Cancer Initiative has taken an exclusive license to...
2020-02-18 10:00 AM EST